Navigation Links
Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Date:1/25/2012

ently available therapies, indicate that CMX001 has the potential to improve outcomes for immunosuppressed patients.

CMX001 Study 201 is a randomized, placebo-controlled Phase 2 study of CMX001 as prophylaxis for CMV in hematopoietic cell transplant recipients.  230 subjects were randomized (3:1) to receive CMX001 or placebo in five sequential, dose-escalating cohorts.  Subjects were dosed either once weekly (QW) or twice weekly (BIW) for nine to 11 weeks until post-transplant week 13, with a four-to-eight week follow-up period. 

To date, more than 700 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.  Recently presented data from 183 patients who received CMX001 within a compassionate setting indicated that CMX001 showed no indication of the myelosuppression or nephrotoxicity associated with currently available antiviral therapies.

About Chimerix
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  Utilizing proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. 

In addition to the company's development of its lead candidate, CMX001, for transplant recipients,  CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, with the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised, or a household contact of a contraindicated individual, and thus not candidates to receive a smallpox vaccine (for additional information, please see http://www.bt.cdc.gov/agent/s
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences
2. Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
3. Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
4. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
5. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
6. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
7. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
8. Chimerix to Present at the Citi 2011 Global Health Care Conference
9. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... , ROCKVILLE, Md., Dec. 9 Novavax, ... 25, 2009, it closed its previously announced public offering of ... Novavax received net proceeds from the sale of the ... approximately $21 million, which will be used for preclinical studies ...
... , GAITHERSBURG, Md, Dec. 9 Lentigen Corporation, ... of lentiviral gene delivery technologies, announced today that it ... business innovation research (SBIR) grant for a program on ... using Lentivirus". In this program, Lentigen will collaborate ...
Cached Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... 01, 2014 Currently, scientists continue ... treatments for Alzheimer's disease (AD), which reflects their ... regarding the diagnosis of the disease, especially in ... appropriate diagnostic tests. In 2014, after decades ... breakthroughs in the medicine world, there are still ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... There may be a biological reason why depression and ... compared to men. Studying stress signaling systems in animal ... to low levels of an important stress hormone and ... "This is the first evidence for sex differences ...
... Using an electron microscope, scientists at EMBL captured this snapshot ... role in how zebrafish perceive the world around them. This ... picture taken from a gallery of abstract paintings, but the ... help from scientists at the European Molecular Biology Laboratory (EMBL) ...
... ... healthcare appointments online. , ... Chicago, IL (PRWEB) June 15, 2010 -- ZocDoc, the website to find ... area. The company’s move was chosen by thousands of users, who were asked which ...
... ... in Texas, today announced it was named one of the “Best Places to Work” in ... the Small Business Category (companies with 1-50 employees), earning this prestigious accolade just 18 months ... ...
... ... , ... 15, 2010 -- The United Soybean Board highlights all the various ways ... among other things, farmers utilizing modern animal agriculture practices – such as specialized housing ...
... , ... multi-ethnic society is still the foundation of our strength. One online magazine and website, ... about race, culture, and ethnicity. , ... (PRWEB) June 15, 2010 -- Despite the heated debates raging over ...
Cached Medicine News:Health News:Higher anxiety, depression among women may have basis in cell signals 2Health News:Chicago Votes for Improved Healthcare with ZocDoc 2Health News:San Antonio Business Journal Names BMI of Texas One of the Best Places to Work in San Antonio 2Health News:San Antonio Business Journal Names BMI of Texas One of the Best Places to Work in San Antonio 3Health News:United Soybean Board New Site Features Farmers', Ranchers' Animal Care 2Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 2Health News:Why A Multi-Racial, Multi-Ethnic Society Needs Open and Sustained Dialogue 3
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
System, English (Continental cord), 230 VAC....
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Medicine Products: